Home/Pipeline/BARHEMSYS® (amisulpride) injection

BARHEMSYS® (amisulpride) injection

Postoperative nausea and vomiting (PONV)

Approved/CommercialDivested

Key Facts

Indication
Postoperative nausea and vomiting (PONV)
Phase
Approved/Commercial
Status
Divested
Company

About Eagle Pharmaceuticals

Eagle Pharmaceuticals is a specialty pharmaceutical company with a strategic focus on critical care and oncology, dedicated to discovering, developing, and marketing medicines that matter. The company has transitioned from a portfolio-based model to one with a diversified pipeline of internally and externally sourced candidates, including novel new chemical entities. Recent strategic moves include the divestiture of BARHEMSYS to sharpen its focus on its core pipeline and commercial assets like BYFAVO.

View full company profile

Therapeutic Areas

Other Postoperative nausea and vomiting (PONV) Drugs

DrugCompanyPhase
Astressin PlatformSentia Medical SciencesPre-clinical
APONVIE®Heron TherapeuticsApproved